Stifel on Ligand Pharma (LGND): 'positioned for continued traction owing to MRK’s new ownership of Ohtuvayre'
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $230.00 price target on Ligand Pharma (NASDAQ: LGND)The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
